Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BeiGene, Boehringer Ingelheim Enter Supply Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

BeiGene, Boehringer Ingelheim Enter Supply Agreement

For tislelizumab, BeiGene’s investigational anti-PD-1 antibody

By: Betsy Louda

, Contract Pharma

BeiGene and Boehringer Ingelheim have entered into a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibody. 

 

Under the terms of the supply agreement, Boehringer Ingelheim will manufacture tislelizumab in China under an exclusive multi-year arrangement, with contract extension possible. In addition, BeiGene also obtained certain preferred rights for future capacity expansion by Boehringer Ingelheim in China.

 

“As we advance tislelizumab towards potential regulatory approval and commercialization in China, we are pleased to have secured our commercial product supply from Boehringer Ingelheim BioXcellence, one of the world’s leading biopharmaceutical contract manufacturers. Over the years, working with the Boehringer Ingelheim team for our clinical supply, we have built a strong partnership based on a shared commitment to providing high-quality medicine to patients,” said John V. Oyler, founder, chief executive officer, and chairman of BeiGene.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics